The short version
- Why people research itLibido, hormonal signaling and reproductive / sexual function.
- What the evidence isApproved for osteoporosis and breast-cancer risk reduction, with large randomized data — MORE and STAR.
- What to watchA swollen, painful calf or sudden breathlessness.
How Raloxifene works
A SERM is not a weak estrogen and it is not an anti-estrogen. It is the same molecule behaving oppositely in two tissues at the same time, and raloxifene is the cleanest example there is: agonist in bone and liver, antagonist in breast and uterus Hochner-Celnikier 1999.
The structure. Brzozowski 1997 solved the ligand-binding domain of the estrogen receptor twice: with 17β-estradiol at 3.1 Å and with raloxifene at 2.6 Å. Both ligands occupy the same pocket in the core of the domain, but with different binding modes, and each induces a distinct conformation in the transactivation domain.
- Oral
On the goal map: Bone remodeling — building vs preserving (Joints & bone)
Research on Raloxifene4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Approved for postmenopausal osteoporosis and breast-cancer risk reduction.
Human clinical evidence
Approved for osteoporosis and breast-cancer risk reduction, with large randomized data — MORE and STAR. STAR compared it head-to-head with tamoxifen and found comparable risk reduction with fewer uterine events.
Correlative data
Used for gynecomastia, where a small published trial in adolescents reported better response than tamoxifen. Real-world use is much lower than tamoxifen's.
How the mechanism reads
A second-generation SERM — antagonist in breast and uterus, agonist in bone. The uterine antagonism is the key difference from tamoxifen and the reason for the better endometrial safety profile.
MechanisticSame class thromboembolic risk, since hepatic estrogen-receptor agonism drives it in both.
Mechanistic
Sources
- Brzozowski AM, Pike AC, Dauter Z. Molecular basis of agonism and antagonism in the oestrogen receptor.. Nature 1997 · PMID 9338790
- Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.. JAMA 1999 · PMID 10517716
- Vogel VG, Costantino JP, Wickerham DL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.. JAMA 2006 · PMID 16754727
- Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.. N Engl J Med 2006 · PMID 16837676
- Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.. Drug Metab Dispos 2002 · PMID 12019197
- Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application.. Eur J Obstet Gynecol Reprod Biol 1999 · PMID 10428318
- Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.. J Pediatr 2004 · PMID 15238910
- US Food and Drug Administration. EVISTA (raloxifene hydrochloride) tablets, for oral use - full prescribing information.. FDA approved labeling, revision 2018
Raloxifene safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Past clot in the leg or lung, or a clotting gene such as Factor V Leiden: SERMs raise clot risk.
- Past stroke or a high stroke-risk profile.
- Pregnancy or trying to conceive: it is an estrogen-receptor modulator with fetal risk.
- Unexplained uterine bleeding or active estrogen therapy.
- Liver impairment: raloxifene is cleared through the liver and bile and levels rise.
What’s expected
- Blocks estrogen in breast tissue and acts like it in bone.
- Hot flashes and leg cramps.
- Lower LDL cholesterol.
- No uterine lining stimulation, unlike tamoxifen.
Watch for
- A swollen, painful calf or sudden breathlessness.
- Sudden loss of vision or speech.
- A new breast lump.
- Chest pain while using Raloxifene.
Labs that tell you it’s working
- Lipid Panel
- Estradiol, Sensitive [LC/MS-MS]
- Factor V Leiden Mutation, DNA
- Comprehensive Metabolic Panel (CMP)
A SERM: antagonist in breast and uterus, agonist in bone, so clotting risk and lipid shift follow from estrogen-receptor agonism. PMID 10517716 PMID 16837676
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “Low T? Rule Out the Reversible Causes First” panel, explained
Raloxifene FAQ4 common questions
- Is Raloxifene approved for human use?
- Raloxifene is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Raloxifene researched for?
- Libido, hormonal signaling and reproductive / sexual function.
- Which labs show whether it's doing anything?
- Lipid Panel; Estradiol, Sensitive [LC/MS-MS]; Factor V Leiden Mutation, DNA; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Raloxifene: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



